Nouscom extends Series C round to $82m for cancer vaccine trials
Summary
The vaccine is currently being tested in a Phase I/II trial (NCT04041310) in combination with MSDs blockbuster checkpoint inhibitor Keytruda (pembrolizumab). One of these trials (NCT05078866) is testing NOUS-209 as a monotherapy in Lynch Syndrome (LS) carriers, who have a higher risk of developing cancer. The raised funds will also be used for Phase II trials evaluating NOUS-PEV in conditions with unmet needs.Nouscoms platform has caught the eye of big players in the pharma industry. BioNTechs personalised RNA vaccine for pancreatic cancer reignited buzz around the therapies, which have been shown to have high efficacy. Several milestones for the space occurred in 2023, ranging from Phase III trials to multi-billion dollar deals.Sales of immuno-oncology products, which include cancer vaccines, are forecast to exceed $150bn in sales by 2028, according to a report from GlobalDatas Pharma Intelligence Centre.